FDA clears first 3-D printed prescription drug

FDA clears first 3-D printed prescription drug
This product image provided by Aprecia Pharmaceuticals shows Spritam 750 mg, foreground, and 1000 mg tablets. Aprecia Pharmaceuticals on Monday, Aug. 3, 2015 said the FDA approved Spritam for adults and children who suffer from certain types of seizures caused by epilepsy. The tablet is manufactured in a layered process via 3-D printing and dissolves when taken with liquid. (Aprecia Pharmaceuticals via AP)

The Food and Drug Administration has approved the first prescription drug made through 3-D printing: a dissolvable tablet that treats seizures.

Aprecia Pharmaceuticals said Monday the FDA approved its drug Spritam for adults and children who suffer from certain types of seizures caused by epilepsy. The tablet is manufactured through a layered process via 3-D printing and dissolves when taken with liquid.

The Ohio-based company says its printing system can package potent drug doses of up to 1,000 milligrams into individual tablets. It expects to launch Spritam in the first quarter of 2016.

The FDA has previously approved medical devices—including prosthetics—made with 3-D printing. An agency spokeswoman confirmed the new drug is the first prescription tablet approved that uses the process.

Aprecia said in a statement it plans to develop other medications using its 3-D platform in coming years, including more neurological drugs. The company is privately owned.

Doctors are increasingly turning to 3-D printing to create customized implants for patients with rare conditions and injuries, including children who cannot be treated with adult-size devices. The FDA held a workshop last year for medical manufacturers interested in the technology.


Explore further

FDA cracks down on unapproved ear drops

© 2015 The Associated Press. All rights reserved.

Citation: FDA clears first 3-D printed prescription drug (2015, August 3) retrieved 15 November 2019 from https://medicalxpress.com/news/2015-08-fda-d-prescription-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
8 shares

Feedback to editors

User comments